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Introduction
In order to have a meaningful discussion about any industrial cluster, it is necessary to be 
able to place bounds upon the cluster and to quantify the inputs to it, its outputs and its 
impact on the global industry of which it is a part.   This paper addresses indicators of the 
performance of the Vancouver human heath biotechnology cluster. Separating input and 
output indicators is fairly easy in the case of the biotech industry. The main inputs for the 
cluster are federal (and somewhat provincial) R&D funding going to universities, 
associated teaching hospitals, and research centres, and highly qualified human resources 
(as opposed to inputs of materials and labour as in the case of most manufacturing 
industries). Output indicators from R&D activities are also easy to identify: scientific 
publications and patents. But there are other outcomes that include the commercialization 
of research (via licensing) and the creation of new companies (start-ups).
Biotechnology policy in Canada
The federal government of Canada does not have a formal, written, science and 
technology policy.  However, since the mid-1990s its S&T policy has been remarkable 
consistent.  This unwritten S&T policy can be summarized as follows:
- direct support of basic and early stage applied research in the university sector 
- creation of specialized, decentralized, stakeholder operated granting agencies 
for university-based research (e.g. Networks of Centres of Excellence)
- shift from direct support for industrial S&T and innovation to indirect 
methods (e.g. Scientific Research and Experimental Development tax credit program) 
- reduction of direct R&D spending in government labs, and a consequent focus 
on mission-oriented research 
1 This paper relies heavily on the work of many people. It is based on a paper presented by Monica Salazar 
and the author at the CSIIC Colloquium “Measuring the Impacts of Science”, Montreal, 2004,  entitled “ In 
search of Impact and Outcome Indicators based on Vancouver Biotechnology Cluster Studies”. The current 
paper was presented at a colloquium in Anyang , Korea, in 2004, sponsored by  the Korean Research 
Institute for Human Settlements.
- active recruitment of S&T HQP through repatriation of Canadian emigrants 
and encouragement of immigrants 
- participation in international consortia for big science projects such as NASA 
programs, the Canada-France-Hawaii telescope, etc.
The federal government’s policy on biotechnology and related industries is circumscribed 
by constitutional limitations in that health (as with all other social programs, such as 
education) is the responsibility of the provincial governments2. This does not stop the 
federal government from supporting biotechnology:  The federal government circumvents 
this largely political issue by, on the one hand, providing research grants directly to 
academic researchers through granting agencies such as the Canadian Institutes of Health 
Research (CIHR) and the Natural Sciences and Engineering research Council (NSERC), 
and secondly by setting up ‘arm’s length” research networks, such as the Networks of 
Centres of Excellence and Genome Canada, which actually administer and distribute 
research funding. The federal department of health, Health Canada, is not a major funder 
of external research, although it has a number of laboratories of its own that carry out 
work on infectious diseases and regulatory issues. It should be noted that biotechnology-
related research funding is an order of magnitude greater than government investment in 
ICTs.3
The federal government generally provides direct funding for research; industrial 
research in biotechnology (as well as other areas) is supported indirectly through tax 
credits. The tax credit programs provides direct funding rebates to small firms, which are 
in pre-production (and Canadian-controlled) and tax credits against taxes payable on 
profits for larger, more established, firms.
There are two other policies of note.  The first is to encourage the formation of strong, 
industry-led associations, such as Biotech BC and Biotech Canada, which act as 
exchanges for pre-competitive intelligence and personal networking, and the 
encouragement, through tax measures, of private, non-profit, associations dedicated to 
medical research.  These associations provide the only way in which individual 
Canadians can direct their donations to specific biotechnological research – they 
represent a grass-roots research program that is not duplicated in other disciplines.
The nature of regional innovation systems
A number of Canadian authors (see for example, Holbrook and Wolfe, 2005) have 
described how Canada, a large, geographically and culturally diverse federation, is 
composed of a number of regional systems of innovation.  These regional systems have a 
number of systemic differences. P.Cooke (1998) has proposed a taxonomy that 
differentiates regional systems of innovation in a two dimensional matrix.  This matrix 
has a governance dimension (how technology is transferred in the economy) and a 
2 This is equally true of other disciplines.  Education, including post-secondary education, is a provincial 
responsibility, and thus research in post-secondary institutions has to be managed without direct funding 
transfers from the federal government to the provincial governments.
3 See Holbrook and Clayman (2004).  On the other hand, Canada has a well-developed ICT research 
capability through Nortel Ltd., which is based in Ottawa, and which grew out of federal research programs in 
that city.
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dimension that describes the innovation process in the business sector (how firms see 
themselves and their innovative processes)4.  
The table below shows the regions originally chosen by Cooke as exemplifying his 
taxonomy, Canadian provinces chosen by Holbrook and Salazar (2006), with equivalent 
Korean regions chosen by Chang (2005):
4 The reader should refer to Cooke’s paper (1998) for a full description of this paradigm
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Table 1:  Regional Systems of Innovation
Governance →
Business
Innovation ↓
Grassroots Networked Dirigiste
Localized Tuscany Denmark
Pohang City
Tohuku (Japan)
Jinju City
Interactive Catalonia
Saskatchewan
Manitoba
Baden-Wurtemburg
Alberta
British Columbia
Seoul City
Quebec
Daejon City
Globalized California
Ontario
North-Rhine
Gyonggi Province
Singapore
Note: Regions in italics are from either Salazar and Holbrook or Chang.  Those in regular 
font are from Cooke.
In the case of British Columbia, the geographic region in question really the Greater 
Vancouver Regional District, which is a geographic areas surrounded by the sea and by 
mountains.  Vancouver is a well-defined economic region which hosts a number of high-
tech industrial clusters, which beside biotechnology, includes wireless, fuel cells, and 
new media.  All of these have the common feature that Vancouver does little actual 
manufacturing; rather it develops the intellectual property required for innovative 
products, while the actual products are manufactured elsewhere (often in lower wage-rate 
venues, closer to the final consumers).
The Innovation Systems Research Network project:  the Vancouver biotechnology 
cluster
Why choose Vancouver5 biotech cluster as a case study? Because, on the one hand, 
biotech is clearly a research-based industry, therefore university research and public R&D 
funding play a key role in the development of a cluster. On the other hand, Vancouver 
seems to be very successful according to different studies and indicators, such as number 
of bio-scientists , the number of spin-off companies from universities and the survival 
rate of these companies , the commercialization of R&D , and the ability to retain and 
attract talent.
The Innovation Systems Research Network (ISRN) is a cross-disciplinary, national 
network of researchers drawn from five regional nodes based in Atlantic Canada, Québec, 
Ontario, and Western Canada. In 2001 ISRN launched the five-year project “Innovation 
Systems and Economic Development: The Role of Local and Regional Clusters in 
Canada” funded mainly by the Social Science and Humanities Research Council 
5 This paper refers to  Vancouver, but for cluster indicator purposes it is  really the Lower Mainland of BC, which 
includes Vancouver, Burnaby, Richmond, Delta, North Vancouver, New Westminster, Abbotsford, and Langley, among 
other smaller cities. More than 50% of the firms are located in the city of Vancouver, followed by Burnaby with 15% of 
the enterprises. We purposely exclude Victoria taking into account that “no matter what method of transportation is 
used, it takes over two hours to travel from one city centre to the other (other than by scheduled helicopter service). 
Two hours is often taken as the outer boundary for travel time across the geographic area of a cluster” .
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(SSHRC), with some additional support from other federal and provincial agencies. This 
project is investigating how local networks or clusters of firms and supporting 
infrastructure of institutions, businesses and people in communities across Canada 
interact to spark economic growth6. Research is focused on 27 clusters –of which 
Vancouver biotech is one - across the five regions in Canada in newly emerging 
knowledge-intensive areas as well as in more traditional sectors. It covers large 
metropolitan settings located near research-intensive universities as well as rural settings. 
One of the objectives of the ISRN study is to develop a methodology to examine regional 
innovation systems and their constituent features, and to define the necessary and 
sufficient conditions for the continued existence of the clusters in the regional innovation 
systems.
Finally, through the analysis of this data we may be able to identify the necessary and 
sufficient conditions are for a cluster to survive in the longer term. Up to now ISRN 
researchers have identified some of the necessary conditions, like a world-class research 
university and a cosmopolitan community . Yes the questions remains, what are the 
sufficient conditions for continued existence? It is the intent of this paper to identify 
outcome indicators that can assist in answering the above question. The paper is 
organized in four main sections, starting with an overview of the Vancouver biotech 
industry. In the second section we will present the main inputs to the cluster, followed by 
the presentation of some of its outcomes. Finally, we will draw some conclusions and set 
up the next step of this on-going research project.
Sources of information
Results presented in this paper will make reference to different quantitative and 
qualitative studies. Quantitative information will mainly make reference to Statistics 
Canada, especially the 2001 Biotechnology Use and Development Survey. The other 
studies are: the Innovation Systems Research Network (ISRN) cluster project, the 
Vancouver Economic Development Commission (VEDC) report “Vancouver: A North 
American Biotechnology Centre” of 2002, a series of reports made for the Canadian 
Foundation for Innovation (CFI) regarding cluster development, and three reports 
commissioned by the Canadian Biotechnology Strategy.
The VEDC, BC Biotech Association, and Discovery Parks (DPI) undertook a study using 
the methodology of the 2002 Brookings Institution report Signs of life: The growth of 
biotechnology centers in the U.S.7. BC Biotech and DPI provided the data and VEDC did 
the analysis of the information. The set of indicators used to determine the relative 
success of the biotechnology industry were organized around two main areas: research 
activity (funding from CIHR8 and CFI, and number of patents issued 1990-1999), and 
commercialization (venture capital funding to biopharmaceuticals 1995-2001, value of 
R&D partnerships with pharmaceuticals 1996-2001, number of biotechnology companies 
6 To date, four books have been published with proceedings of the ISRN annual conferences, which include 
interim reports  of  the  project,  as  well  as  contributions  from national  and  international  scholars  .  More 
information on the project can be found in www.utoronto.ca/isrn.
7 See http://www.brook.edu.
8 The Canadian Institutes for Health Research (CIHR) is one of the four Canadian granting agencies.
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with 100 or more employees in 2001, and number of start-up companies 1991-2001) . 
The third group of reports used for this paper, is a couple of studies on clusters, looking at 
the role of spin-offs  and R&D funding .
Finally, in 2003 the Canadian Biotechnology Strategy commissioned three studies related 
to: i) alliances between firms within and between clusters; ii) scientific publications and 
collaborations (a bibliometric study conducted by the Canadian Science and Innovation 
Indicators Consortium); and iii) a survey on eleven biotech firms from across the country 
(conducted by Strategic Health Alliances). These reports were later summarized by the 
National Research Council (NRC).
The Statistics Canada “Biotechnology Use and Development Survey, 2001” was 
undertaken in two phases. First a short survey to identify firms actually involved in 
biotech was sent to 11262 firms. Later the full survey was sent to 900 firms, with an 84% 
rate of response. Not-for-profit organization, universities, hospitals, government 
laboratories, and contract research organizations were excluded, as well as firms with less 
than 5 employees and less than $100,000 in R&D expenditures. 
For the ISRN project, the research team designed a set of interview guides (for 
companies, research institutes, government agencies, financial institutions, and civic 
associations), based on the OECD Oslo Manual and Statistics Canada innovation surveys. 
For the Vancouver biotech cluster study 50 interviews were conducted in two rounds, 
during the Summers of 2002 and 2003, comprising 23 biotech/biomed firms, 7 
government agencies, 7 contract research and manufacturing organizations, 5 venture 
capital companies (VCC), 5 law and consultancy firms, 2 research institutes, and 1 civic 
association.
What is “biotech”?
Before we go any further it is crucial to state what we mean by “biotechnology industry”. 
Generally, this industry makes reference to small and medium-sized companies 
specialized or dedicated just to biotechnology9, excluding multinational pharmaceutical 
firms. For the purpose of the ISRN study, we used the OECD definition of biotechnology, 
which is the same one that Statistics Canada used for its biotech survey:
"Biotechnology is the application of S&T to living organisms as well as parts, products 
and models thereof, to alter living or non-living materials for the production of 
knowledge, goods and services”.
The OECD uses as an indicative, but not exhaustive list of biotechnology techniques and 
applications as an interpretative guide, which includes:
DNA (the coding): genomics, pharmaco-genetics, gene probes, DNA 
sequencing/synthesis/amplification, genetic engineering. 
9 Some  authors  refer  to  these  companies  as  “specialized  biotechnology  firms”  (SBFs)  or  “dedicated 
biotechnology firms” (DBFs). For the purpose of this study we will use the term biotech firms, understanding 
these specialized SMEs.
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Proteins and molecules (the functional blocks): protein/peptide 
sequencing/synthesis, lipid/protein glyco-engineering, proteomics, hormones, and 
growth factors, cell receptors/signalling/pheromones. 
Cell and tissue culture and engineering: cell/tissue culture, tissue engineering,  
hybridisation, cellular fusion, vaccine/immune stimulants, embryo manipulation. 
Process biotechnologies: Bioreactors, fermentation, bioprocessing, bioleaching,  
bio-pulping, bio-bleaching, biodesulphurization, bioremediation, and 
biofiltration. 
Sub-cellular organisms: gene therapy, viral vectors. 
Some of the differences on the data presented below can be attributed to definitional 
issues, since some institutions talk about biotech industry, others about life sciences 
(especially institutions with various stakeholders), a broader concept, encompassing other 
industries such as medical devices. In addition, we differentiate between human health 
care biotech and other applications, such as agriculture, aquaculture, environment, etc. 
Characteristics of the Vancouver biotech cluster
BC Biotech states10 that the biotech industry in the province is comprised of 90 privately 
owned firms, 12 contract research organization (CROs), 3 contract manufacturing 
organizations (CMOs), 6 clinical trial organizations, 7 venture capitalists, 8 government 
organizations, 3 not-for-profit organizations, 3 research institutes. Most of these located 
in the Lower Mainland and few in the Greater Victoria area. Some of these organizations 
perform more than one function. 
Information from another source  provides a broader picture of the life sciences cluster in 
BC, which comprises: 43 private firms that develop pharmaceutical, therapeutics and 
genomic products for human health care, and more than 100 enterprises that develop 
medical devices, bioinformatics, nutraceuticals, diagnostics, agriculture and aquaculture 
products. 
BC life sciences industry is mainly oriented to human health care - 60% of firms are 
oriented to biopharmaceutical and biomedical applications – with few agrobiotech firms 
in the province.
For making comparisons more meaningful between Canadian cities/clusters – due to 
large differences in size - we have to determine a normalizing factor. We have different 
options: population, highly qualified personnel, or number of biotech innovative firms. 
NRC uses population, Clayman and Holbrook use highly qualified personnel, and we 
propose number of innovative firms. Depending on the case, a different normalization 
variable will be used, the one that makes more sense.
10 See web page (industry backgrounders) http://www.bcbiotech.ca.
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Compared to Montréal and Toronto biotech clusters11, Vancouver is smaller in number of 
firms, employment, revenues, and amount of capital raised, but invests more money in 
R&D and has more bio-scientists12 (see table 1). Queenton and Niosi suggest that bio-
scientists play a major role in the location and growth of biotechnology firms . This 
statement gives a promising future to Vancouver’s biotech industry. 
The biotech industry in the Lower Mainland is composed mainly of young and small 
firms13, inspired by QLT - created in 1981 – which is the largest (around 300 employees) 
privately owned and highly successful biotech firm, which can be considered the star firm 
of the cluster - but not an anchor firm. At present there are more medium sized 
companies, and some are following the successful path of QLT (see table 2 for size 
distribution of biotech innovative firms). 
Here it is important to introduce an issue that refers to the way statistics are presented in 
Canada, which hinder somewhat cluster studies based on official data. Statistics Canada 
generally doesn’t provide data at the metropolitan level because of confidentiality 
concerns14. During the process of doing this research and writing the paper Industry 
Canada made available to the ISRN research team selected data for biotechnology 
companies at the city level, which allowed for more meaningful comparisons between 
clusters. However, Holbrook and Clayman’s claim is still relevant:
“In Canada, given its geography, any cluster, existing or putative, is  
almost always linked to a single city or metropolitan area.  Regardless of  
the means through which clusters are stimulated they must be analyzed on 
a municipal basis.  Thus in order to analyze federal research support at  
the cluster level, data on expenditures must be collected by city and 
regional municipalities and, where there is more than one university per 
urban entity, these university activities must also be aggregated” ).
In the table below some basic indicators are presented for the three major human health 
biotech clusters, although the data refers to all biotech firms. 
Table 1 Comparison of Canadian biotech clusters
11 Other Canadian cities claim to have a biotech cluster, but according to the NRC, Montréal, Toronto and 
Vancouver are really the major human health clusters in the country, Edmonton would be the fourth one to 
consider . For the purposes of this study we will just make reference to the first three.
12 They established four categories of bio-scientists: bio-superstar, bio-star, bio-collaborator type A, and bio-
collaborator  type  B.  Differences  between  them  refer  to  the  number  of  patents  granted  and  annual 
publications .
13 See in Biotechnology in BC 2004, the official magazine of BC Biotech Association a list of the core BC 
Biotech member companies classified by stage of development, fields of study, tools and diseases. It can 
also be found in its web page.
14 For instance, in a recent study by Statistics Canada on the emerging geography of new economy analysis 
is done at the provincial and urban level, but the data presented at the city level is aggregated by city size, 
that means that large cities (population greater than one million) are grouped in one category, then medium-
sized cities, etc.
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Cluster Number of 
biotech 
innovative 
firms
Biotech 
Revenues 
(millions 
of 
dollars)
Biotech 
business 
R&D 
expenditures 
(millions of 
dollars)
Number of 
employees in 
biotech-related 
responsibilities
Number of 
bio-scientists
(1)
Montréal 80.0 1017.0 113.0 2935.0 70.0
Toronto 55.0 1094.0 85.0 2661.0 47.0
Vancouver* 48.0 NA 258.0 1701.0 80.0
Subtotal 
major clusters
183.0 2111.0 456.0 7297.0 197.0
Total Canada 375.0 3569.0 1337.0 11897.0 430.0
Source: Statistics Canada Biotechnology Use and Development Survey - 2001; provided 
by Industry Canada; (1) Qeenton and Niosi, 2003.
Note: * Vancouver R&D expenditures do not include large firms because of 
confidentiality requirements.
The youth of Vancouver biotech firms can also be appreciated in the low revenues and 
high R&D spending, and their size can be measured by the number of employees. 
Vancouver has a bigger proportion (36 out of 48) of small firms (less than 50 employees) 
compared to Montréal and Toronto; Montréal has the largest share of large companies 
(more than 150 employees).
Table 2 Size distribution of innovative firms in major biotech clusters
City Small % Mediu
m
% Large % Total %
Montréal 49 41.2 15 38.5 16 64.0 80 43.7
Toronto 34 28.6 15 38.5 6 24.0 55 30.1
Vancouver 36 30.3 9 23.1 3 12.0 48 26.2
Total major 
clusters
119 100 39 100 25 100 183 100
Source: Statistics Canada Biotechnology Use and Development Survey - 2001; provided 
by Industry Canada
Key Features of the Cluster
Vancouver’s biotech cluster has some very distinct characteristics15. The first question to 
ask is if firms consider themselves to be part of a network of related firms in the region 
(ie: a cluster): 59% of firms recognize there is a cluster even if loosely connected, and 
33% say that they are not part of it, even if they usually acknowledge its existence. When 
we look at the cluster networking patterns and interactions between firms and various 
actors, we found no vertical integration (suppliers are from all over the world), and little 
horizontal integration or competition among local firms. In respect of suppliers, it is 
15 The data presented below is taken from the ISRN data base, making reference to 27 firms, biomed firms 
and contract research organizations. 
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important to mention that few firms in the Lower Mainland actually manufacture their 
main outcome is intellectual property as such. The few firms that have products in the 
market have manufacturing agreements with companies from outside the region. 
Therefore, suppliers are not key actors in the biotech cluster (70% of firms affirm that 
suppliers do not play a role in the growth of the company – see table 3). In relation to 
competition, each biotech company works in a very specific niche of technologies or 
products16, knowledge comes mainly from research results of local scientists, so there is 
little technological competition among firms. In addition, the local biotech firms have 
little commercial relations among themselves. They neither compete for local talent – we 
will explore this issue later in the paper - nor for market (which is global), they just 
compete for venture capital funding, which is scarce locally. And that is changing too, 
since local companies have been successful in getting funding from American, European 
and Asian VCC17. Finally, in relation to collaborations and alliances, there are few 
companies that have some kind of association with other local firms, but strategic 
partnerships with non-local firms - especially big pharmaceuticals – are quite important; 
55.6% of companies affirm that they have alliances with multi-nationals, which could be 
at different phases: drug development, clinical trials, production, or marketing.
The role of location and lifestyle are clearly a contributing factor to the development of 
the biotech cluster in Vancouver, based on the responses obtained in three different 
questions. First, we asked why they were located in the region: 85% of firms say that 
their location is due to founders being from Vancouver who have close relationships with 
university labs and R&D institutions; in addition 18.5% affirm that it is a nice place to 
live. Second, we asked about the advantages of being in Vancouver: 48% of the 
interviewees said that the advantages are due to the ‘cluster’ existence and the facilities 
associated with it (R&D labs, VC, etc.), and 22% said that the city is nice, which makes it 
easier to attract people to live here. And finally, when we asked about contributing factors 
for the growth of the firm and the cluster, co-location with other firms was important, but 
most important, was the existence of specialized research institutes and universities, and 
the accompanying factor of supply of workers with particular skills responses (see table 3 
below).
Table 3  Most important factors in the local/regional economy that contribute 
to or inhibit the growth of Vancouver biotech firms
Factors Not applicable Inhibit Contribute
Co-location with other firms in the same 
industry
8 1 18
Supply of workers with particular skills 2 4 21
Physical, transportation or communication 
infrastructures
12 4 11
Availability of financing 6 6 15
Specialized research institutions and 
universities
3 0 24
16 See BC Biotech list of core member companies by fields of study, tools and diseases, available in its 2004 
magazine and its web page.
17 According to Biotechnology in BC (pg. 52) –the official magazine of BC Biotech Association - life sciences 
public and private companies raised $1.03 billion companies in 2003, via different mechanisms, VC, IPOs, 
equity financing; Vancouver biotech companies received around 92% of that money.
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Specialized training or educational institutions 8 1 18
Presence of key suppliers and/or customers 19 3 5
Government policies or programs 5 7 15
Other 20 2 5
Source: ISRN data base
Role of universities and research centres: Inputs and outputs 
As mentioned before, the biotechnology industry is heavily dependent upon scientific 
research, therefore the role of universities, research hospitals and R&D institutions, and 
the availability of R&D funding are crucial. However, the impact of universities cannot 
be traced easily regarding cluster creation and development. A recent report about 
universities and industrial clusters in selected US states, affirms that:
“Regional efforts to develop industry cluster increasingly include 
universities as central assets. Unfortunately, little is understood about 
how universities impact the development of regional industry clusters.  
[…] The characteristics of the cluster are as important as the 
characteristics of the university if there is to be any regional impact.  
Universities cannot defy the forces of the market. The university can 
produce the seeds of new firms and industries, but the region must offer a 
fertile climate for them to flourish” .
The NRC report identifies few metrics to measure cluster activity, starting with the size 
of the population, followed by the concentration of public funded research . We propose 
three different measures (one input and two outputs): public R&D funding, patents, and 
scientific publications.
R&D funding
In Canada, as in most countries, granting agency expenditure data is not usually des-
aggregated or classified by industrial sectors or clusters, but is normally presented by 
subject or discipline, which makes it difficult to analyze the impact of R&D funding in 
the promotion of regional clusters and industries. Data can be classified by province or 
city according to the location of the receptor institution. 
In relation to biotech R&D money, there are four different sources in Canada: the 
Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering 
Research Council (NSERC), the Canada Foundation for Innovation (CFI)18, and Genome 
Canada; CIHR being the most important granting agency in the case of biotech19. From 
the table below we can observe that British Columbia receives a proportional share of 
18 The mandate for CFI is to fund research infrastructure.
19 CIHR funding is divided in four categories: biomedical; clinical health systems and services; and social, 
cultural, environmental, population health. Most of the money is dedicated towards biomedical and clinical 
research, though for simplicity we will use all CIHR funding.
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infrastructure funding from CFI (using population as the normalizing factor), but less 
than its proportional share of CIHR funding. In addition, the three provinces where the 
major human health biotech clusters are located (Ontario, Quebec and British Columbia) 
account for over 90% of the R&D funding for health.
Table 4 Provincial share of R&D funding for health-related research 
Province Share of CIHR 
funding 1999-2001 
(average per year) 
%
Share of CFI 
health sector 
allocations 1997-
2002 %
Share of 
population %
Ontario 41.7 39.1 37.8
Quebec 30.3 29.9 24.1
British Columbia 8.4 14.5 13.2
Subtotal 92.8 96.9 84.8
Source: VEDC, 2002; based on data provided by CFI and CIHR.
Using a different source, figure 1 shows the expenditures on biotech (in this case CIHR 
and NSERC) for major Canadian cities. Again we can clearly appreciate that Montréal, 
Toronto and Vancouver are the major recipients of those funds.  What is interesting from 
that table is the distribution of NSERC biology funding, much less concentrated in the 
three major biotech clusters.
Holbrook and Clayman proposed several tests to qualify and characterize the impact of 
R&D funding on cluster creation and development. The first test is to determine R&D 
intensity (normalization of granting agency expenditures by population), which show the 
degree of R&D activity of a city. This data can be refined by HQP intensity, which is the 
ratio of HQP20 to total labour force. In their own words: 
“The award of R&D grants by the agencies’ peer review committees is at  
arm's length and represents an informed assessment of the quality of R&D 
proposals. When normalized by population or by the number of highly 
qualified personnel in a region, these ratios are good indicators of the 
“productivity” of the region in terms of intellectual property.  A useful  
way of comparing the research intensities of Canadian cities is to plot  
them against the proportion of highly qualified persons (HQP) in the 
population, which is a good measure of its receptor capacity” .
20 According to Statistics Canada 2001 Census Data HQP is defined as persons between 25 and 64 with at 
least a Bachelors degree.
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Figure 1 - R&D funding for biotech (CIHR and NSERC biology) 2001
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Source: Holbrook and Clayman 2004.
Note: KWG stands for Kitchener, Waterloo and Guelph, the only cities from the group 
that do not have medical schools.
Following Holbrook and Clayman analysis, the combination by city of R&D intensity 
and HQP intensity give us an estimative of the response of how the city is actually 
making use of R&D expenditures, if it is providing more or less qualified personnel to 
make an adequate use of that money. We encounter different situations in the Canadian 
case, two worth mentioning (see example of CIHR funding below), are:
- large urban centres, such as Toronto and Vancouver, with high levels of 
absolute R&D expenditures and large numbers of HQP in non-R&D activities, 
which yield non-extreme levels of R&D intensity; and
- "university towns" such as Kingston, where the university is a major factor in 
the local economy, have high R&D expenditures and low numbers of HQP, 
resulting in high R&D intensity which may not reflect to true state of the local 
economy” . 
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Year-to-Year Changes in CIHR R&D Intensity for 15 Major Cities
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From the figure above it can be easily appreciated that Canada is keeping the pace 
in R&D funding for health research in relation to the increase in the highly 
qualified personnel; R&D spending is increasing at a higher rate than the increase 
in HQP. Different results were obtained for NSERC funding – flat arrows or slight 
increase– which could somewhat show the implicit S&T policy in Canada (i.e. 
health research is a priority).
Patenting activity
Patents as said before are an important output of scientific and technological activity. 
Because of the close relationships between the biotech industry and universities and R&D 
institutions, it is important to study those relations through patents (i.e. licensing of 
university technology, or shared patents between companies and researchers). By 
studying patents we are also able to illustrate the involvement of scientists in the creation 
of biotech start-ups. This is also a measure of knowledge spill-over occurring within 
clusters. According to Queenton and Niosi’s study on bio-scientists, a high proportion of 
Canadian university researchers are related to biotech companies through patents. In their 
own words:
“Contrary to our first assumptions on the importance of discoveries of 
genetic sequences, we found that for Canadian biotech firms what matters 
the most is the number and quality of patents that bio-scientists of  
different categories bring to those enterprises. Thus, the innovation output  
represented by patents and by patent citation constituted a real factor on 
employment growth” .
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Regarding patenting activity in Vancouver we have found interesting data (see table 5). 
Companies and UBC are the major patent holders, with similar numbers of patents 
granted. Interestingly, but not surprising, Vancouver organizations are not interested in 
patenting nationally (with the Canadian Intellectual Property Office); their target is 
basically the US. However it could be said that drugs are developed for a global market 
attended by multinational pharmaceuticals.
Table 5 Patenting activity in Vancouver 1990-1999
Organization US Patent 
and 
Trademark 
Office
Patent 
Cooperation 
Treaty
Canadian 
Intellectual 
Property 
Office
European 
Patent 
Office
Total patents 
by 
organization
Share %
Vancouver 
companies
67 51 69 187 52.8
SFU 10 5 1 16 4.5
UBC 43 90 11 7 151 42.7
Total patents 
by office
120 146 11 77 354 100.0
Source: PATSCAN; taken from VEDC, 2002.
Queenton and Niosi affirm that the interaction between scientists and firms are much 
more than knowledge transfer, there are also market/monetary interests involved. In their 
own words:
“The analysis of the presence of star scientists in biotechnology firms and 
the identification of the roles they played in the formation and the survival 
of those firms will give us good indicators about the dynamic interaction 
between different types of activities in biotechnology. Scientists in 
university departments and in public research centres increasingly become 
full economic actors” .
Following this argument, Queenton has further studied the kind of relationships that bio-
scientists have with firms and what kind of role they perform. In the case of Vancouver, 
more half of researchers (57%) keep the link to the company through the patent, 36.5% 
have a seat on the board of directors, and fewer (6.1%) have the double connection. In 
relation to roles, few of Vancouver researchers (10.4%) act as founders of the company 
(10.4%), a relative high number (42.6%) have an specific function within the company, 
while a third of them keep both affiliations (to the firm and the university or R&D 
institution) .  
Scientific publications
Due to the close connection of the biotechnology industry to university research, it is 
important to analyze the patterns and trends of scientific publications. As an example, the 
Canadian Science and Innovation Indicators Consortium prepared for the Canadian 
Biotechnology Strategy a bibliometric study that tries to identify research clusters in 
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biotechnology in Canada. Looking at this document and the summary report by NRC, 
there is nothing out of the ordinary; the number of publications per city/cluster follows 
the pattern of research funding .
Table 6 Scientific publications in biotechnology 1996-2000
Cluster Number of 
publications
Share by 
city/cluster %
Provincial 
share %
Montréal 1432 21.2 28.7
Toronto 1337 22.7 40.9
Vancouver 787 12.5 13.7
Total 6305 100.0
Source: . 
Note: The provincial share is obtained based on larger number of publications.
Apart from only looking at the number of papers published, we can see how productive 
the scientists are by comparing the number of publications with the R&D funding they 
receive (table 7). Some authors affirm that for doing this kind of measurement one should 
consider a time lag of 5 to 7 years, after the funding occurs. Of course this is not a perfect 
match (person by person, or institution by institution), since it is aggregated, in this case 
at the city level. Different reports give various results on this issue. It seems that there are 
several factors which may affect these results: i) the categorization of scientific 
publications; ii) the granting agencies included; and iii) the time period considered, both 
for publications and R&D funding. Table 7 below present some data based on two 
different studies, and without taking into account the time lag suggested, showing a high 
rate of publication for Toronto, and a quite low rate for Vancouver. One possible 
explanation why Vancouver scientists publish less is because of their closer connections 
to biotech spin-offs firms, which discourages publication; the opposite would be 
applicable to Toronto.
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Table 7 Biotech scientific publications and public R&D funding for biotech
Cluster Number of 
Publication
s 1999 (1)
Number of 
Publication
s 2000 (1)
R&D 
funding for 
biotech 2001 
(2)
Publications 
(2000) per million 
dollars invested 
(2001)
Montréal 284 291 67,996,641 4.3
Toronto 253 279 52,234,867 5.4
Vancouver 177 165 49,018,171 3.4
Subtotal 
major clusters
714 735 169,249,679 4.3
Canada * 1283 1291 391,648,9590 4.9
Source: (1) Godin et al (2003); (2) Holbrook & Clayman (2004).
Note: Total publications for Canada include only 14 major clusters. R&D funding 
includes CIHR and NSERC (biology) funding for 28 cities.
As a way of concluding this section, we can quote the VEDC report “Vancouver: A North 
American Biotechnology Centre”, which affirms that “we do more with less”, which 
means that despite the low level of research activity (funding and patenting) Vancouver 
rates high in the commercialization index . Comparing Vancouver21 results with the 
average of 52 American metropolitan centres, Vancouver’s research index is 0.34, and 
commercialization index is 2.50 (see overall results of the study in table 8).
21 VEDC did not have data available at the city level therefore they used provincial data, which for the case 
of BC is not too problematic since approximately 87% of biotech firms are located in the Lower Mainland 
(Vancouver for short). 
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Table 8 Measures of biotechnology activity in metropolitan centres
Lower 
Mainland/Southern 
Vancouver Island
52 US cities average
Biomedical research 
capacity and activity
CIHR/CFI funding 2000 US$34.5 millions US$225.5 millions
Patents files at US Patent 
Office 1990-1999
354 676
Research Index 0.34 1.0
Biotechnology 
commercialization
Venture capital 1998-2001 US$204.1 millions US$191.3 millions
Value of R&D alliances US$290.0 millions US$203.0 millions
Biotechnology firms with 
100 or more employees
6 6
New biotechnology firms 
1991-2001
60 9
Commercialization Index 2.50 1.0
Source: VEDC, 2002 
These results were confirmed by NRC, which on a per capita basis they found Vancouver 
has a better record in firm generation, venture capital funding, than either Montréal and 
Toronto, but fall behind in CIHR funding .
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Outcomes of R&D funding
What comes next is the more interesting story about the cluster. From the university point 
of view an outcome of its scientific and technological activity will be the 
commercialization of research, via licensing and spin-offs22. Some universities actually 
support and encourage this while others do not. Intellectual property rights (IPR) 
practices across Canadian universities are very diverse; there is no such thing as the 
Bayh-Dole act in the country. In the case of Vancouver, while the University of British 
Columbia (UBC) and Simon Fraser University (SFU) have different IPR policies, both 
encourage commercialization of R&D. In addition to licensing, there are spin-off 
companies, which can also be considered as an outcome indicator of R&D funding. 
Turning into private sector firms, established companies or newly created start-ups which 
license technology from universities (input), have as outputs of their innovative activities 
new technological products/services and processes23. There are some other 
22 Statistics Canada defines a spin-off as “a new firm created to transfer and commercialize inventions and 
technology developed in universities, firms and laboratories”, 1999 Biotechnology Use and Development 
Survey. 
23 It  is  important to note that Vancouver’s biotech firms produce mainly intellectual  property rather than 
products as such .
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consequences24 of their activities: in the medium-term to create employment, to attract 
talent to the region; and in the longer-term to improve the quality of life (e.g. improve 
diagnostic methods, find cures to diseases, decrease mortality rate). We will focus on the 
medium-term outcomes of R&D activity both from universities and firms.
University Spin-offs
The majority of biotechnology companies in BC have been spun-off from the province’s 
universities, affiliated teaching hospitals and public sector research institutions; UBC 
being the major source of new firms, basically because it has a medical school. Since the 
creation of the University-Industry Liaison Office (UILO) in 1984, UBC has spun off till 
March 2003 48 life sciences companies25, of which 31 are still active in the region, 5 
acquired or merged (just one of them not locally present). Taking into account the 
common yardstick of 5 years minimum of survival, 28 companies (out of 38) founded 
before 2000 are still active, that is a 74% survival rate. Clayman and Holbrook (2004) 
found that 23 biotech firms were created in Vancouver between 1995 and 2001 and 19 
were still active in the summer of 2003 –that is how they defined the survival rate of the 
companies- 14 spun out of UBC, and 5 spun out of SFU. 
Using spin-offs as an outcome indicator carries some methodological problems. On the 
one hand, to date no government systematically collects data on spin-offs. The more 
comprehensive data available is the survey of technology commercialization activities in 
North American Universities conducted by the Association of University Technology 
Managers. On the other hand, there is no accepted definition of “spin-offs”. Furthermore 
each definition varies. For example, there is a general belief that spin-offs result from 
research done at universities and R&D centres and sometimes companies. However, 
companies consider themselves spin-offs only when there is a licensing agreement or 
shared patent. In contrast, universities hold having a university professor as a founder of a 
company is enough to be considered a university spin-off. Thus it is easy to understand 
the methodological difficulties encountered when using the term “spin-offs”. For our 
purposes we will use the term from the firms’ standpoint.
24 Statistics Canada differentiates between outcome and impact indicators of science and technology activity 
in a useful way: outcomes are medium-term consequences of such activities, and impacts are longer-term 
consequences of activities, linkages and outcomes.
25 http://www.uilo.ubc.ca/tech_transfer/spin_off/index.htm 
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Table 9 Biotech spin-offs companies 1995-2001
Clusters Active Inactive Total
Survival 
rate %
Active spin-
offs per 
100.000 HQP
Montréal 31 13 46 67.4 6.0
Toronto 23 9 32 71.9 2.7
Vancouver 19 7 26 73.1 5.6
Source: Clayman and Holbrook, 2004
Note: Vancouver includes University of British Columbia and Simon Fraser University; 
Toronto refers only to University of Toronto, and Montréal includes the universities of 
McGill and Montréal.
What is important to keep in mind is that the overriding goal of university spin-off is not 
to provide further income to the universities, but to create well-paid new jobs in the 
region. For doing so, they need to survive, and hopefully to stay in the city where they 
were created, so they can contribute to the further development of the local cluster. It is 
important to note that the national survival rate is 73%, the same as Vancouver’s survival 
rate; Montréal and Toronto have lower rates of survival . In their own words: 
“Companies spun off from university research appear to be a particular way of 
effective means of technology transfer out of universities, leading to job creation 
and wealth creation. [But for] spin-off companies to contribute to economic 
growth they must survive and succeed” .
Venture capital
The health care biotech industry requires large amount of money to go through the drug 
development and approval processes, which means that public R&D funding and research 
capacity – embedded in universities - are not enough to make a cluster flourish; it 
requires large amounts of risk capital. A good indicator of this capacity is the venture 
capital money raised by biotech companies.
Vancouver is home to eight venture capital companies (VCC). The city is not considered 
a major financial centre in Canada, local VCC have small amounts of money to invest 
compared to other Canadian or US VCC. What has been seen in recent years is that a 
number of firms have been able to attract money from other markets (principally the US). 
This is not to discount the role of the local VCC firms as they play an important role in 
the process. Even with limited amounts of cash, their money acts as a leverage, and more 
important, they can keep an eye on these firms, providing information to foreign 
investors.
Looking just at Vancouver’s data, we can appreciate that local biotech companies have 
substantially improved its performance in this respect. According to table 10, the amount 
of venture capital financing, the number of transactions, and the average investment per 
transaction have all increased between1998 and 2001. This trend is very important 
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because biotech spin-offs do not have a bright future if they cannot access money to 
finance the costly and lengthy process of drug development. But when compared with the 
other two major clusters (see table 11), we see that Vancouver companies raise less 
money than their Montréal and Toronto counterparts, in absolute terms, and also less by 
innovative firm.
Table 10 Vancouver Venture Capital Financing 1998-2001
Year Venture capital 
investment (US$ 
millions)
Number of financings 
per year
Average investment 
per transaction (US$ 
millions)
1998 16.6 11 1.5
1999 35.6 15 2.4
2000 45.1 13 4.1
2001 106.5 11 9.7
Total 204.1
Source: Macdonald and Associates 
Comparing the major biotech clusters, it is not surprising that Montréal has attracted the 
most venture capital, but what is of interest is that Toronto does not get a bigger share of 
that money considering the infrastructure it has, and in the case of Vancouver, even if it is 
not a financial centre, still receives a significant amount of those funds. These results 
maybe related to distinct IP university practices.
Table 11 Table Venture capital – life sciences industry
Cluster
VC $000s
2002
VC $000s
2003
VC (2002) per 
innovative firm (2001)
Montreal 167.7 152.9 2.1
Toronto 100.6 74.5 1.8
Vancouver 71.9 43.1 1.5
Subtotal major 
clusters 340.2 270.5 1.9
Total Canada 479.0 392.0 1.3
Source: Macdonald & Associates26
Human resources, talent, and employment
From the science and technology indicators point of view, the role of human resources, 
especially of highly qualified personnel (HQP), can be seen from two different angles. On 
the one hand, HQP is an input to R&D activities. On the other hand, from a broader 
perspective (cluster development), HQP is both an input to economic activity but also an 
outcome of the success of the local economy attracting and retaining personnel. However, 
26 Data obtained from their web site: http:// www.canadavc.com, on May 2004.
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from either perspective, it is clear is that we need to analyse in greater detail the role that 
HQP (or talent using Richard Florida’s wording), and the quality of life of places play in 
cluster emergence and development. In this respect, Gertler and associates have noted:
“To be successful in this emerging creative age, regions must develop,  
attract and retain talented and creative people who generate innovations,  
develop technology-intensive industries and power economic growth. Such 
talented people are not spread equally across nations or places, but tend 
to concentrate within particular city-regions. The most successful city-
regions are the ones that have a social environment that is open to 
creativity and diversity of all sorts” .
From a cluster perspective, recent studies have proposed that industrial agglomeration is 
due to much more than solely economic reasons. Richard Florida has stated that cities 
attract talent through two interrelated mechanisms: market forces (ie. industries and firms 
than create the demand for talent) and non-market forces, which can be referred as set of 
place-based characteristics, such as amenities, lifestyle options, types of people and the 
like. He states:
“People with high levels of human capital tend to co-locate to realize 
gains in productivity. Put another way, the basic mechanisms of city 
formation, growth and structure turn on the process of productive agents 
selecting locations that reinforce productivity. This is very different from 
the cost-minimization and firm linkage theories of clustering that 
dominate much of the economic geography” .
Empirical studies, with the objective of testing the above statements, were 
conducted for some American  and Canadian cities , and in both cases was found 
that social and cultural factors affect agglomeration. 
For Canada the findings were similar to the US but stronger relationships were found. 
Vibrant local population and openness to diversity attract highly qualified people to 
Canada. The conclusions of the report say:
“There appears to be a strong set of linkages between creativity, diversity,  
talent and technology-intensive activity that are driving the economies of  
Canada’s city-regions” . 
The American report about the role of universities on cluster development states that one 
of the key variables to study the relation between the two is through employment. They 
used two measures: employment change 1975-2000 – they used a long-range perspective 
to avoid short-term changes - and, location quotient – to determine the significance of 
regional share in particular industries .
Some analysts claim that for measuring the real growth of the cluster we should use the 
number of employees in biotech-related activities, not total employment in those firms, 
since there are a large proportion of personnel dedicated to other activities. Employment 
data show us interesting patterns for the major biotech clusters: they have 33% of the 
23
population, 30% of general employment, 47% of HQP, and 61.4% of biotech 
employment. Therefore, the concentration of biotech activity is clearly represented in 
these three cities. Additionally, the last column shows that Toronto innovative companies 
employ more people than Montreal and Vancouver, which share similar averages.
Table 12 Human resources data
Cluster Population 
(1) 
Employmen
t (1) 
Highly 
qualified 
personnel 
(2)
Number of 
employees in 
biotech-
related 
responsibilities 
(3) 
Share of 
biotech 
employment
Average 
of 
employees 
per 
innovative 
firm
Montréal 3,507,200 1,679,000 514,560 2935 24.7 36.7
Toronto 4,882,500 2,413,000 866,840 2661 22.4 48.4
Vancouver 2,076,100 995,320 340,215 1701 14.3 35.4
Subtotal 10,465,800 5,087,320 1,721,615 7297 61.4 39.9
Canada 31,021,300 17,046,800 3,676,630 11897 100.0 31.7
Source: (1) Statistics Canada web site; (2) Clayman & Holbrook, 2004; Statistics Canada 
Biotechnology Use and Development Survey – 2001, provided by Industry Canada.
Since biotechnology is a research-intensive sector, it is logical that it is also a heavy user 
of highly skilled labour. From table 13 we can appreciate that 59.5% of the jobs in major 
clusters are scientific research/direction and technician categories, and the national 
average is 49% . The table below also identifies some interesting facts about the 
employment structure of biotech companies. 
Vancouver has more scientific personnel, Toronto more people in finance/marketing (big 
difference) and regulatory/clinical affairs, and Montréal more production personnel.  The 
concentration of employees in the scientific research/direction and technician categories 
for Vancouver (67.4) is much higher than the national average, but also when compared 
to Montreal and Toronto. This structure of employment clearly shows the stage of the 
companies (early stage versus mature company) but also their emphasis 
(research/innovation versus production).
What we have observed in Vancouver biotech cluster in relation to the local talent pool, is 
that senior management is scarce locally (CEOs and regulatory/drug development experts 
especially), and technical and scientific personnel is available (graduating from local 
universities and technical institutions). It seems that mobility at higher positions is high, 
but there is not much mobility at the scientific and technical level, but certainly people 
stay in the region. The lack of specialized management expertise in Vancouver is due to 
the absence of pharmaceutical companies in the region. Analyses based on data collected 
through the Statistics Canada biotech survey, small companies tend to recruit personnel 
directly from universities, but as they grow they turn to other companies to look for new 
workers . What may happen in the future in Vancouver, as biotech jobs shift from small to 
medium-sized firms, is that we will see more mobility among companies, which is not 
happening at present.
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Table 13 Distribution of biotechnology employees in innovative SMEs
 Montré
al 
% Toronto % Vancouver % General 
%
Scientific 
research & 
direction
509 35.3 354 27.7 416 41.4 34.4
Technicians 400 27.7 274 21.5 261 26.0 25.1
Regulatory 
/Clinical 
affairs
52 3.6 109 8.5 28 2.8 5.1
Production 154 10.7 51 4.0 60 6.0 7.1
Finance/ 
Marketing
125 8.7 336 26.3 54 5.4 13.8
Management 189 13.1 135 10.6 120 11.9 11.9
Other 13 0.9 17 1.3 66 6.6 2.6
Total major 
clusters
1442 100 1276 100 1005 100 100
Source: Statistics Canada Biotechnology Use and Development Survey - 2001; provided 
by Industry Canada
Additionally, while conducting the ISRN interviews the research team noticed that in 
various biotech firms there were a number of key personnel who moved from various 
Canadian provinces, the US, and European countries27. Therefore, we undertook a simple 
Internet-based research, looking at companies’ web sites, which provided academic 
information on their top management personnel. We surveyed 44 firms, of which 30 
reported on their HQP. Results are presented in Table 12.  Approximately 30% of people 
have a Ph.D. degree from a local university, while 70% in-migrate from other Canadian 
provinces or other countries28. 
Table 14  Academic background of top management personnel (PhD level)
Origin Number of employees 
with PhD degree
Share%
SFU 3 4.8
UBC 16 25.4
Rest of Canada 9 14.3
US 16 25.4
UK 11 17.5
Rest of the world 8 12.7
Total 63 100.0
Source: CPROST – SFU
27 See in the official magazine of BC Biotech Association “Biotechnology in BC 2004”, the article by Rachana 
Raizada telling the story of Jeffrey Baccha, Inimex CEO who moved from San Francisco to Vancouver.
28 At present we are re-doing this work, checking the information on the web sites and interviewing firms, 
gathering more information about management teams of all biotech firms in Vancouver.
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Based on the ISRN interviews, the quality of life Vancouver offers is a major reason for 
companies and people to choose it, thus it can be said it is a contributing factor to the 
development of the cluster. It looks as though large firms and a larger pool of companies 
– that allow more mobility among firms- are not necessarily a prerequisite to attract 
employees as could be the case of Montréal and Toronto. The success of Vancouver could 
be due to the fertile ground that universities, R&D centres, and firms provide for highly 
qualified people to develop their careers and have a satisfying lifestyle.  As Florida noted 
for US cities: 
“The ability to attract talent is the fundamental dimension of city and 
regional growth. This contrasts with the preoccupation in much of the 
academic literature and in economic development practice that 
emphasizes the attraction of firms and the formation of industrial clusters.  
It is talent that orients the location decisions of firms and which underpins 
the formation of industrial clusters” .
Conclusions
Several factors and conditions can be attributed to the creation and success of regional 
clusters, such as the existence of strong university research-oriented, availability of 
funding by public granting agencies, an entrepreneurial spirit, and a favourable location 
and environment so that talented people are attracted to those places. Research capacity is 
a necessary but not sufficient condition. As Griller and Viger (2004) pointed out: “to 
succeed, increased research capacity, has to be overlapped with venture capital, and an 
entrepreneurial culture”.
Vancouver seems to fulfill all those requirements. Once people come to Vancouver they 
tend to stay there (sticky labour). UBC research is the driving force behind the biotech 
industry in the city. R&D funding has not been as important as one would have expected, 
considering the growth of the cluster, but that has been replaced with an entrepreneurial 
force and availability of high risk capital29.
Do the indicators tell us that Vancouver is significantly different in structure, not just size, 
from Toronto and Montréal? Is the Vancouver biotech industry an emergent or a research-
based cluster? We could affirm that the structure is different and that Vancouver is really 
an R&D-based cluster: local firms invest more on R&D, there is a large pool of bio-
scientists -who are highly productive (especially in terms of patents)-, employ more 
scientific and technical personnel, and do little manufacturing. These numbers were high 
in absolute terms and when normalized either by innovative firms or HQP. Additionally, 
S&T indicators show an interesting picture of Vancouver biotech cluster; we do not 
perform particularly well in terms of inputs and outputs (exception of patents), but we do 
29 Queenton (2004) has analyzed the various biotech clusters in Canada in terms of “stars”, researchers 
who have significant numbers of papers and patents. By this measure Vancouver, with 80, comes slightly 
ahead of Montreal (70) and well ahead of Toronto (40).  Other Canadian centres fall well behind these three 
cities. 
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in terms of outcomes (venture capital, attraction of talent, university spin-offs). Why is 
that? Are we missing any measures, particularly inputs? Maybe we have to broaden the 
way we study (measure performance) science, technology and innovation systems; we 
need to analyze especially the role of highly qualified personnel –their mobility and 
where and how they agglomerate.
Do the indicators tell us that Vancouver is a viable cluster? It looks as though the model 
of being an IP producer cluster works, that is, it seems that we do not need a 
manufacturing facility or pharmaceutical company to further develop the cluster. If the 
largest company of the region relocates or disappears, we do not believe that the integrity 
of the existing cluster would be jeopardized. In addition, as previously mentioned, 
Vancouver outperforms in attracting people, money and having an entrepreneurial 
capacity.  New ideas, new firms, new people will come.
What policy advice could we derive from the indicators? The environment (city life and 
facilities) is key to developing the cluster. Richard Florida’s conclusion certainly applies 
to Vancouver:
“People are attracted to real places. Cities and regions that facilitate the 
co-location of people that results in resource mobilization, new knowledge 
generation, and new ideas, reduces the costs associated with generating 
and transmitting ideas and knowledge” 
27
Acknowledgements
This paper relies heavily on the work of many people. As noted it is based in part in a 
paper presented by Monica Salazar and the author at the CSIIC Colloquium “Measuring 
the Impacts of Science”, Montreal, 2004,  entitled “In search of Impact and Outcome 
Indicators based on Vancouver Biotechnology Cluster Studies”.  The author is also 
indebted for the work done by his research assistants on this project over the past three 
years: Monica Salazar, M., Nicola Crowden, Shawna Reibling, Katie Warfield, and 
Naomi Weiner. (2004)
References
28
